¼¼°è ±Û·çÄ«°ï À¯»ç ÆéƼµå 1(GLP-1) ÀÛ¿ëÁ¦ ½ÃÀå : À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, À¯Åë °æ·Îº°, Åõ¿© °æ·Îº°, Áö¿ªº°, ±¹°¡º° ºÐ¼®, ½ÃÀå ÀλçÀÌÆ®, ¿¹Ãø
Global Glucagon-Like Peptide 1 Agonist market : Analysis by Type, End-Use, By Distribution Channel, By Route of Administration, By Region, By Country: Market Insights and Forecast
»óǰÄÚµå : 1420111
¸®¼­Ä¡»ç : Azoth Analytics
¹ßÇàÀÏ : 2024³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,450 £Ü 3,506,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 2,950 £Ü 4,222,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ±Û·çÄ«°ï À¯»ç ÆéƼµå 1(GLP-1) ÀÛ¿ëÁ¦ ½ÃÀå ±Ô¸ð´Â 2020³âºÎÅÍ 2023³â±îÁö º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 20.6%ÀÇ ¼ºÀåÀ» º¸¿´½À´Ï´Ù. 2022³â ½ÃÀå ±Ô¸ð´Â 187¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â¿¡ 1,335¾ï ´Þ·¯¿¡ À̸¦ Àü¸ÁÀÔ´Ï´Ù. GLP-1 ÀÛ¿ëÁ¦ ¼ö¿ä´Â ¼¼°èÀûÀ¸·Î È®´ëµÇ°í ÀÖÀ¸¸ç, ¼±ÁøÁö¿ª°ú °³¹ßµµ»óÁö¿ªÀÌ ¸ðµÎ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ½ÅÈï°æÁ¦±¹¿¡¼­´Â T2DMÀÇ À¯º´·üÀÌ »ó½ÂÇϰí GLP-1 ÀÛ¿ëÁ¦ Ä¡·á¸¦ Æ÷ÇÔÇÑ È¿°úÀûÀÎ ´ç´¢º´ °ü¸® Àü·«ÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ½ÃÀå¿¡´Â ´Ü½Ã°£ ÀÛ¿ëÇü°ú Àå½Ã°£ ÀÛ¿ëÇüÀÇ ´Ù¾çÇÑ GLP-1 ÀÛ¿ëÁ¦°¡ ÀÖ¾î, ÀÇ·á Á¦°ø¾÷ü³ª ȯÀÚ¿¡°Ô ´Ù¾çÇÑ ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°Àº ÇÇÇÏ ÁÖ»ç ¶Ç´Â °æ¿ì¿¡ µû¶ó °æ±¸ Åõ¿©µË´Ï´Ù.

GLP-1 ÀÛ¿ëÁ¦´Â T2DM ȯÀÚÀÇ Ç÷´ç Á¶ÀýÀ» °³¼±Çϴµ¥ È¿°úÀûÀÎ °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖÀ¸¸ç, Á¾Á¾ HbA1c ¼öÄ¡¿Í °øº¹½Ã Ç÷´ç ¼öÄ¡ÀÇ ÀúÇϸ¦ ÃÊ·¡ÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ¾à¹°Àº üÁß °¨¼Ò¸¦ µ¿¹ÝÇϹǷΠºñ¸¸ ´ç´¢º´ ȯÀÚ¿¡°Ô ƯÈ÷ À¯¿ëÇÕ´Ï´Ù.

ÀϺΠGLP-1 ÀÛ¿ëÁ¦´Â ÀÓ»ó½ÃÇè¿¡¼­ ½ÉÀå ¸¶ºñ, ³úÁ¹Áß, ½ÉÇ÷°ü »ç¸ê°ú °°Àº ÁÖ¿ä À¯ÇØ ½ÉÇ÷°ü »ç°Ç(MACE)À» °¨¼Ò½ÃŰ´Â µî ½ÉÇ÷°ü°è¿¡ À¯ÀÍÇÑ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿¬±¸ °á°ú´Â T2DM°ú ½ÉÇ÷°ü Áúȯ(CVD)ÀÇ Áöº´ÀÌ Àְųª ½ÉÇ÷°ü À§ÇèÀÌ ³ôÀº ȯÀÚ¿¡¼­ GLP-1 ÀÛ¿ëÁ¦ÀÇ Ã¤Åà Ȯ´ë¿¡ ±â¿©ÇÕ´Ï´Ù.

GLP-1 ÀÛ¿ëÁ¦´Â ÁÖ·Î ÇÇÇÏ ÁÖ»ç·Î Åõ¿©µÇÁö¸¸, ȯÀÚÀÇ º¹¾à Áؼö¿Í Æí¸®¼ºÀ» Çâ»ó½Ã۱â À§ÇØ, °æ±¸ Á¦Á¦³ª ÁÖ 1ȸ ÁÖ»ç µîÀÇ ´ëü Åõ¿©¹ýÀÇ °³¹ßÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº Ä¡·á ¾îµåÈ÷¾î·±½º¿¡ ´ëÇÑ ÀáÀçÀûÀÎ À庮À» ÇØ°áÇϰí ȯÀÚ ¸¸Á·µµ¸¦ ³ôÀÌ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù.

º» º¸°í¼­´Â ¼¼°è ±Û·çÄ«°ï À¯»ç ÆéƼµå 1(GLP-1) ÀÛ¿ëÁ¦ ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Áö¿ª ¹× ºÎ¹® ºÐ¼®, ÁÖ¿ä µ¿Çâ°ú ±âȸ µîÀÇ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½ÃÀå ¹è°æ

Á¦2Àå Àü·«Àû ±ÇÀå »çÇ×

Á¦3Àå ¼¼°è ±Û·çÄ«°ï À¯»ç ÆéƼµå1(GLP-1) ÀÛ¿ëÁ¦ ½ÃÀå : ½ÇÀû°ú ¿¹Ãø(2020³â-2030³â)

Á¦4Àå ¼¼°è ±Û·çÄ«°ï À¯»ç ÆéƼµå 1(GLP-1) ÀÛ¿ëÁ¦ ½ÃÀå : Áö¿ª ºÐ¼®

Á¦5Àå ¾Æ¸Þ¸®Ä«ÀÇ ±Û·çÄ«°ï À¯»ç ÆéƼµå1(GLP-1) ÀÛ¿ëÁ¦ ½ÃÀå : ½ÇÀû°ú ¿¹Ãø(2020³â-2030³â)

Á¦6Àå À¯·´ÀÇ ±Û·çÄ«°ï À¯»ç ÆéƼµå1(GLP-1) ÀÛ¿ëÁ¦ ½ÃÀå : ½ÇÀû°ú ¿¹Ãø(2020³â-2030³â)

Á¦7Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Û·çÄ«°ï À¯»ç ÆéƼµå1(GLP-1) ÀÛ¿ëÁ¦ ½ÃÀå : ½ÇÀû°ú ¿¹Ãø(2020³â-2030³â)

Á¦8Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ±Û·çÄ«°ï À¯»ç ÆéƼµå1(GLP-1) ÀÛ¿ëÁ¦ ½ÃÀå : ½ÇÀû°ú ¿¹Ãø(2020³â-2030³â)

Á¦9Àå ½ÃÀå ¿ªÇÐ

Á¦10Àå »ê¾÷ »ýÅÂ°è ºÐ¼®

Á¦11Àå °æÀï Æ÷Áö¼Å´×

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Executive Summary

Azoth Analytics has released a research report titled "Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market (2024 Edition)" which provides a complete analysis of the Global Glucagon-Like Peptide 1 (GLP-1) Agonist industry in terms of market segmentation By Type (Tirzepatide, Semaglutide, Dulaglutide, and Other Types), By Distribution Channel (Clinics, Ambulatory Surgical Centers, and Hospitals), By Route of Administration (Oral, and Parenteral) By End-Use (Type 2 Diabetes, NASH, and Obesity), for the historical period of 2020-2023, the estimates of 2023 and the forecast period of 2024-2030.

The research report covers a detailed analysis of the Region (Americas, Europe, Asia Pacific, and Middle East and Africa) and Countries (United States, Canada, UK, Germany, France, Italy, India, China, Japan, South Korea). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities, and demand forecast. The research report also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

The Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market showcased growth at a CAGR of 20.6% during 2020-2023. The market was valued at USD 18.75 Billion in 2022 which is expected to reach USD 133.5 Billion in 2030. The demand for GLP-1 agonists extends globally, with both developed and developing regions contributing to market growth. Emerging economies are witnessing a rising prevalence of T2DM, driving the need for effective diabetes management strategies, including GLP-1 agonist therapies. The market includes a variety of GLP-1 agonist drugs, both short-acting and long-acting formulations, offering different options for healthcare providers and patients. These drugs are administered via subcutaneous injection or, in some cases, orally.

GLP-1 agonists are known for their efficacy in improving glycemic control in patients with T2DM, often leading to reductions in HbA1c levels and fasting plasma glucose levels. Additionally, these drugs are associated with weight loss, making them particularly beneficial for obese individuals with diabetes.

Several GLP-1 agonists have demonstrated cardiovascular benefits in clinical trials, including reductions in major adverse cardiovascular events (MACE) such as heart attack, stroke, and cardiovascular death. These findings have contributed to the growing adoption of GLP-1 agonists in patients with T2DM and established cardiovascular disease (CVD) or high cardiovascular risk.

While GLP-1 agonists are primarily administered via subcutaneous injections, efforts are underway to develop alternative delivery methods, such as oral formulations and once-weekly injections, to improve patient adherence and convenience. These innovations aim to address potential barriers to treatment adherence and enhance patient satisfaction.

Scope of the Report

Table of Contents

1. Market Background

2. Strategic Recommendations

3. Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

4. Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Regional Analysis

5. Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

6. Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

7. Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

8. Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

9. Market Dynamics

10. Industry Ecosystem Analysis

11. Competitive Positioning

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â